Cargando…

Repurposed Drugs in Gastric Cancer

Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Araújo, Diana, Ribeiro, Eduarda, Amorim, Irina, Vale, Nuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822219/
https://www.ncbi.nlm.nih.gov/pubmed/36615513
http://dx.doi.org/10.3390/molecules28010319
_version_ 1784865892071374848
author Araújo, Diana
Ribeiro, Eduarda
Amorim, Irina
Vale, Nuno
author_facet Araújo, Diana
Ribeiro, Eduarda
Amorim, Irina
Vale, Nuno
author_sort Araújo, Diana
collection PubMed
description Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease.
format Online
Article
Text
id pubmed-9822219
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98222192023-01-07 Repurposed Drugs in Gastric Cancer Araújo, Diana Ribeiro, Eduarda Amorim, Irina Vale, Nuno Molecules Review Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease. MDPI 2022-12-30 /pmc/articles/PMC9822219/ /pubmed/36615513 http://dx.doi.org/10.3390/molecules28010319 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Araújo, Diana
Ribeiro, Eduarda
Amorim, Irina
Vale, Nuno
Repurposed Drugs in Gastric Cancer
title Repurposed Drugs in Gastric Cancer
title_full Repurposed Drugs in Gastric Cancer
title_fullStr Repurposed Drugs in Gastric Cancer
title_full_unstemmed Repurposed Drugs in Gastric Cancer
title_short Repurposed Drugs in Gastric Cancer
title_sort repurposed drugs in gastric cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822219/
https://www.ncbi.nlm.nih.gov/pubmed/36615513
http://dx.doi.org/10.3390/molecules28010319
work_keys_str_mv AT araujodiana repurposeddrugsingastriccancer
AT ribeiroeduarda repurposeddrugsingastriccancer
AT amorimirina repurposeddrugsingastriccancer
AT valenuno repurposeddrugsingastriccancer